Compare · GLP-1 agonist
Tirzepatide vs VK2735
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Tirzepatide | VK2735 | |
|---|---|---|
| Evidence | Strong human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A dual GIP/GLP-1 receptor agonist with strong RCT evidence for type 2 diabetes, weight loss, and sleep apnea; GI side effects are common. | VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown. |
| Full profile → | Full profile → |
Tirzepatide
Tirzepatide is a once-weekly injectable peptide sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight management and sleep apnea). Unlike most compounds we cover here, it has been tested in large, well-run human trials, and the results are unusually consistent. This is not medical advice.
VK2735
VK2735 is an investigational obesity drug from Viking Therapeutics. It belongs to the incretin class — the same broad family as semaglutide and tirzepatide — and has generated a lot of attention because its early human data look strong and because Viking is developing both an injectable and an oral…